Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA

European Journal of Haematology

Volumn 84, Issue 3, 2010, Pages 223-228

  Morabito, Fortunato ^a   Gentile, Massimo ^a   Ciolli, Stefania ^b   Petrucci, Maria T ^c   Galimberti, Sara ^d   Mele, Giuseppe ^e   Casulli, Antonio F ^f   Mannina, Donato ^g   Piro, Eugenio ^h   Pinotti, Graziella ⁱ   Palmieri, Salvatore ^j   Catalano, Lucio ^k   Callea, Vincenzo ^l   Offidani, Massimo ^m   Musto, Pellegrino ⁿ   Bringhen, Sara ^o   Baldini, Luca ^p   Tosi, Patrizia ^q   Di Raimondo, Francesco ^r   Boccadoro, Mario ^o   Palumbo, Antonio ^o   Cavo, Michele ^q   more..

^a Azienda Ospedaliera di Cosenza   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e Divisione di Ematologia   (Italy)

^f Azienda Ospedaliera SS Annunziata   (Italy)

^g Azienda Ospedaliera Papardo   (Italy)

^h PUGLIESE CIACCIO HOSPITAL   (Italy)

ⁱ OSPEDALE DI CIRCOLO   (Italy)

^j CARDARELLI HOSPITAL   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^l OSPEDALI RIUNITI   (Italy)

^m UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

ⁿ REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^o UNIVERSITY OF TURIN   (Italy)

^p FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^q UNIVERSITY OF BOLOGNA   (Italy)

^r Cattedra di Ematologia   (Italy)

more..

Author keywords

Bortezomib; Multiple myeloma; Renal impairment

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; INFECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SEPSIS; STROKE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; GLOMERULAR FILTRATION RATE; HEMATOLOGIC DISEASES; HUMANS; ITALY; KIDNEY DISEASES; MALE; MELPHALAN; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 76249093418     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01385.x     Document Type: Article

References (23)

1. Frankel A, Man S, Elliott P, Adams J, Kerbel KS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000 6 : 3719 3728.
2. Cusack JC Jr., Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 2001 61 : 3535 3540.
3. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001 61 : 3071 3076.
4. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990 150 : 1693 1695.
5. Blade J, Fernandez-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998 158 : 1889 1893.
6. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003 78 : 21 33.
7. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007 48 : 337 341.
8. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007 109 : 2604 2606.
9. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimes and the impact of novel agents. Haematologica 2007 92 : 546 549.
10. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005 23 : 9219 9226.
11. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Haematol 2000 65 : 175 181.
12. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, et al. DOXIL-MMY-3001 Study Investigators. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 2008 8 : 352 355.
13. Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C, et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 2008 49 : 890 895.
14. Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007 92 : 1411 1414.
15. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, et al. SUMMIT/CREST Investigators. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005 103 : 1195 1200.
16. San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008 22 : 842 849.
17. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European group for blood and marrow transplant. Br J Haematol 1998 102 : 1115 1123.
18. Cox DR. Regression models and life tables. J Roy Stat Soc 1972 34 : 187 196.
19. Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008 22 : 1485 1493.
20. Herrera GA. Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory. Ann Diagn Pathol 2000 4 : 174 200.
21. Ivanyi B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med 1990 114 : 986 987.
22. Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, et al. For Greek Myeloma Study Group. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica 2009 94 : 372 379.
23. Ludwig H, Adam Z, Hajek R, Drach J, Adam Z, Labar B, et al. Recovery of renal impairment by bortezomib-doxorubicin-dexamethasone (BDD) in multiple myeloma (MM) patients with acute renal failure. Results from an ongoing phase II study. Blood (ASH Annual Meeting Abstracts) 2007 110 : Abstract 3603.